[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE115999T1 - Ribozyme. - Google Patents

Ribozyme.

Info

Publication number
ATE115999T1
ATE115999T1 AT88311816T AT88311816T ATE115999T1 AT E115999 T1 ATE115999 T1 AT E115999T1 AT 88311816 T AT88311816 T AT 88311816T AT 88311816 T AT88311816 T AT 88311816T AT E115999 T1 ATE115999 T1 AT E115999T1
Authority
AT
Austria
Prior art keywords
ribozymes
Prior art date
Application number
AT88311816T
Other languages
English (en)
Inventor
Wayne Lyle Gerlach
James Phillip Haseloff
Philip Anthony Jennings
Fiona Helen Cameron
Original Assignee
Gene Shears Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27507391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE115999(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gene Shears Pty Ltd filed Critical Gene Shears Pty Ltd
Application granted granted Critical
Publication of ATE115999T1 publication Critical patent/ATE115999T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/10—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds
    • A01N57/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/60—Isolated nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AT88311816T 1987-12-15 1988-12-14 Ribozyme. ATE115999T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPI591187 1987-12-15
AUPI995088 1988-08-19
AUPJ035388 1988-09-09
AUPJ130488 1988-11-04
AUPJ133388 1988-11-07

Publications (1)

Publication Number Publication Date
ATE115999T1 true ATE115999T1 (de) 1995-01-15

Family

ID=27507391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88311816T ATE115999T1 (de) 1987-12-15 1988-12-14 Ribozyme.

Country Status (19)

Country Link
EP (2) EP0321201B2 (de)
JP (1) JP3046318B2 (de)
KR (1) KR970010758B1 (de)
CN (1) CN1102174C (de)
AR (1) AR243935A1 (de)
AT (1) ATE115999T1 (de)
AU (1) AU632993B2 (de)
CA (1) CA1340831C (de)
DE (1) DE3852539T3 (de)
DK (1) DK175956B1 (de)
ES (1) ES2065919T5 (de)
FI (1) FI104562B (de)
GR (1) GR3015374T3 (de)
HU (2) HUT54407A (de)
MC (1) MC2115A1 (de)
NO (2) NO308610B1 (de)
NZ (1) NZ227332A (de)
RO (1) RO114469B1 (de)
WO (1) WO1989005852A1 (de)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019556A (en) * 1987-04-14 1991-05-28 President And Fellows Of Harvard College Inhibitors of angiogenin
CA1340323C (en) * 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5866701A (en) * 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5624824A (en) * 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
DE4091533T (de) * 1989-08-31 1992-01-30
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
DE3933384A1 (de) * 1989-10-06 1991-04-18 Hoechst Ag Multifunktionelle rna mit selbstprozessierungsaktivitaet, ihre herstellung und ihre verwendung
DE3935473A1 (de) * 1989-10-25 1991-05-02 Hoechst Ag Rna mit endonuclease- und antisense-aktivitaet, ihre herstellung und ihre verwendung
EP1418179A3 (de) * 1990-01-11 2006-03-08 Isis Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zum Detektieren und zur Modulation von RNA Aktivität und Genexpression
DE4002885A1 (de) * 1990-02-01 1991-08-08 Hoechst Ag Expression einer multigen rna mit self-splicing aktivitaet
US5519164A (en) * 1990-02-01 1996-05-21 Hoechst Aktiengesellschaft Expression of a multigene RNA having self-splicing activity
US5180818A (en) * 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
WO1991018913A1 (en) * 1990-06-07 1991-12-12 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
WO1991018625A1 (en) * 1990-06-07 1991-12-12 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
ATE150789T1 (de) * 1990-06-19 1997-04-15 Gene Shears Pty Ltd Endonukleasen
US6008343A (en) * 1990-06-19 1999-12-28 Gene Shears Pty. Ltd. Nucleotide based endonucleases
WO1992000080A1 (en) * 1990-06-26 1992-01-09 The Wistar Institute Of Anatomy & Biology Method for treating leukemias
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
CA2088154A1 (en) * 1990-07-26 1992-01-27 Martin Tabler Portable ribozyme cassettes, dna sequences containing them, ribozyme encoded by these dna sequences, and compositions containing these ribozymes
EP0552178B1 (de) 1990-10-12 1997-01-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Abgeänderte ribozyme
NZ241310A (en) * 1991-01-17 1995-03-28 Gen Hospital Corp Trans-splicing ribozymes
NZ314630A (en) * 1991-01-17 2000-11-24 Harvard College Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
FI913197A0 (fi) 1991-07-01 1991-07-01 Xyrofin Oy Nya jaeststammar med reducerad foermaoga att metabolisera xylitol, foerfarande foer bildande av dessa och deras anvaendning vid framstaellning av xylitol.
WO1993014218A1 (en) * 1992-01-13 1993-07-22 Duke University Enzymatic rna molecules
JP3110460B2 (ja) * 1992-04-17 2000-11-20 麒麟麦酒株式会社 複数のウィルスに抵抗性を持つ植物及びその作製法
JPH08500971A (ja) * 1992-06-29 1996-02-06 ジーン・シアーズ・ピーティーワイ・リミテッド 核酸及びウイルス性病原体をコントロールするためのこれらの使用方法
ATE236975T1 (de) * 1992-07-02 2003-04-15 Sankyo Co Haarnadelförmiges ribozym
US5409823A (en) * 1992-09-24 1995-04-25 Ciba-Geigy Corporation Methods for the production of hybrid seed
US5864028A (en) * 1992-11-03 1999-01-26 Gene Shears Pty. Limited Degradation resistant mRNA derivatives linked to TNF-α ribozymes
AU680843B2 (en) * 1992-11-03 1997-08-14 Gene Shears Pty. Limited TNF-alpha ribozymes and degradation resistant mRNA derivatives linked to TNF-alpha ribozymes
US6080851A (en) * 1992-12-04 2000-06-27 American Home Products Corporation Ribozymes with linked anchor sequences
EP0707638A4 (de) * 1992-12-04 1998-05-20 Innovir Lab Inc Regulierbare, therapeutische nukleinsäure und verfahren zur deren verwendung
AU675482B2 (en) * 1992-12-04 1997-02-06 Innovir Laboratories, Inc. Ribozyme amplified diagnostics
FR2701960B1 (fr) * 1993-02-26 2002-09-13 Gene Shears Pty Ltd Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme.
US5817635A (en) * 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
AU5334294A (en) * 1993-10-15 1995-05-04 Dkfz Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Asymmetric hammerhead ribozymes and nucleotide sequences for their construction
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6350934B1 (en) 1994-09-02 2002-02-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid encoding delta-9 desaturase
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US6010904A (en) * 1995-06-07 2000-01-04 The General Hospital Corporation Cell ablation using trans-splicing ribozymes
US6277634B1 (en) 1995-06-07 2001-08-21 Commonwealth Scientific And Industrial Research Organization Optimized minizymes and miniribozymes and uses thereof
US6004806A (en) * 1995-06-07 1999-12-21 Commonwealth Scientific And Industrial Research Organization Optimized minizymes and miniribozymes and uses thereof
MX9800454A (es) * 1995-07-13 1998-04-30 Ribozyme Pharm Inc Composiciones y metodo para modulacion de expresion de genes en las plantas.
US5824519A (en) * 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
WO1998006837A1 (en) * 1996-08-16 1998-02-19 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
BR9808676B1 (pt) 1997-04-15 2010-10-05 construção genética, processos para produzir um polipeptìdeo epoxigenase enzimaticamente ativo, recombinante, e, polipeptìdeo recombinante de ocorrência não natural.
US7589253B2 (en) 1997-04-15 2009-09-15 Commonwealth Scientific And Industrial Research Organisation Fatty acid epoxygenase genes from plants and uses therefor in modifying fatty acid metabolism
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
CA2303759A1 (en) 1997-09-16 1999-03-25 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
DE19741375C2 (de) * 1997-09-19 1999-10-21 Max Planck Gesellschaft Transgene Pflanzen, deren oberirdische Teile früher reifen und vollständig absterben
ATE257392T1 (de) 1997-10-02 2004-01-15 Max Planck Gesellschaft Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
ATE509947T1 (de) 1997-11-18 2011-06-15 Max Planck Gesellschaft Nukleinsäure involviert im responder phenotyp und deren verwendung
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
ES2374534T3 (es) 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Control de la expresión de genes.
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
AU4830899A (en) 1998-06-24 2000-01-10 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
DE19836098A1 (de) 1998-07-31 2000-02-03 Hoechst Schering Agrevo Gmbh Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke
EP1121437B1 (de) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
WO2000028052A2 (en) 1998-11-09 2000-05-18 Planttec Biotechnologie Gmbh Nucleic acid molecules from rice encoding an r1 protein and their use for the production of modified starch
EP2322634B1 (de) 1998-11-12 2014-04-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Chimäre Promotoren, befähigt zur Vermittlung der Genexpression in Pflanzen durch Pathogeninfektion und deren Anwendungen
EP1141331B1 (de) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE)
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AUPQ005299A0 (en) 1999-04-29 1999-05-27 Commonwealth Scientific And Industrial Research Organisation Novel genes encoding wheat starch synthases and uses therefor
ES2250173T3 (es) 1999-07-20 2006-04-16 Gvs Gesellschaft Fur Erwerb Und Verwertung Von Schutzrechten Mbh Nuevo metodo para la generacion y seleccion de plantas de linaza o lino transgenicas.
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
NZ523719A (en) 2000-07-21 2004-11-26 Essentia Biosystems Inc Multi-component biological transport systems
ES2380362T3 (es) 2000-11-09 2012-05-11 Commonwealth Scientific And Industrial Research Organisation Cebada con una actividad reducida en SSII y productos que contienen almidón con un contenido reducido de amilopectina
ITMI20011364A1 (it) * 2001-06-28 2002-12-28 Metapontum Agrobios S C R L Robozima hammerhead specifico per la stearoyl-acp desaturesi di piante oleaginose differenti
ES2358187T3 (es) 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
ATE490322T1 (de) 2001-07-10 2010-12-15 Johnson & Johnson Res Pty Ltd Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen
US8022272B2 (en) 2001-07-13 2011-09-20 Sungene Gmbh & Co. Kgaa Expression cassettes for transgenic expression of nucleic acids
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US7456335B2 (en) 2001-09-03 2008-11-25 Basf Plant Science Gmbh Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
US20070136825A1 (en) 2001-09-18 2007-06-14 Wolf-Bernd Frommer Fusion proteins useful for detecting analytes
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
DE10212892A1 (de) 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
EP1900827A3 (de) 2002-05-21 2008-04-16 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien
CA2542171C (en) 2002-06-26 2015-12-15 Abbott Gmbh & Co. Kg Modulators and modulation of the interaction between rgm and neogenin
WO2004013333A2 (de) 2002-07-26 2004-02-12 Basf Plant Science Gmbh Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
EP2258724A1 (de) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
CA2505776C (en) 2002-12-19 2013-04-02 Bayer Cropscience Gmbh Plant cells and plants which synthesize a starch with an increased final viscosity
WO2006032707A2 (en) 2004-09-24 2006-03-30 Basf Plant Science Gmbh Plant cells and plants with increased tolerance to environmental stress
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
AU2004252186B8 (en) 2003-06-30 2010-06-24 Commonwealth Scientific And Industrial Research Organisation Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom
EP1522594A3 (de) 2003-10-06 2005-06-22 Bayer HealthCare AG Verfahren und kit zur untersuchung von krebs
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US7604947B2 (en) 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3047858A1 (de) 2004-06-10 2016-07-27 Omeros Corporation Verfahren zur behandlung von leiden in zusammenhang mit masp-2-abhängiger komplementaktivierung
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2005261871B2 (en) 2004-07-08 2011-05-26 Dlf Seeds A/S Means and methods for controlling flowering in plants
US8465915B2 (en) 2004-08-02 2013-06-18 Basf Plant Science Gmbh Method for isolation of transcription termination sequences
EP1833291B1 (de) 2004-12-30 2016-10-05 Commonwealth Scientific and Industrial Research Organisation Verfahren und mittel zur verbesserung der darmgesundheit
EP1707632A1 (de) 2005-04-01 2006-10-04 Bayer CropScience GmbH Phosphorylierte waxy-Kartoffelstärke
JP2009510002A (ja) 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 反発誘導分子（ｒｇｍ）タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
CA2628505A1 (en) 2005-11-08 2007-05-18 Basf Plant Science Gmbh Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
WO2007080143A1 (en) 2006-01-12 2007-07-19 Basf Plant Science Gmbh Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
EP2090662A3 (de) 2006-04-05 2012-10-31 Metanomics GmbH Verfahren zur Herstellung einer feinen Chemikalie
EP2030021B1 (de) 2006-05-18 2012-11-21 Andreas Reichert Verfahren zur diagnose mitochondrialer fehlfunktion
US8383597B2 (en) 2006-05-25 2013-02-26 Cornell Research Foundation, Inc. G proteins in tumor growth and angiogenesis
AU2007304837B2 (en) 2006-10-06 2011-09-29 Speedx Pty Ltd Molecular switches and methods for their use
EP2202314B1 (de) 2007-01-15 2014-03-12 BASF Plant Science GmbH Pathogenresistente Pflanzen durch Verwendung von für Subtilisin (RNR9) kodierende Nukleinsäuren
CN101631868B (zh) 2007-02-16 2016-02-10 巴斯福植物科学有限公司 用于在单子叶植物中调节胚特异性表达的核酸序列
US20080260643A1 (en) 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
DE112008001453T5 (de) 2007-05-22 2010-04-29 Basf Plant Science Gmbh Pflanzenzellen und Pflanzen mit erhöhter Toleranz und/oder Resistenz gegenüber Umweltstress und erhöhter Biomasseproduktion-KO
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2040075A1 (de) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Verbindungen und Marker für oberflächenverstärkte Raman-Streuung
EA201070740A1 (ru) 2007-12-14 2010-12-30 Эмджен Инк. Способ лечения перелома кости антителами против склеростина
AU2008340002A1 (en) 2007-12-21 2009-07-02 Basf Plant Science Gmbh Plants with increased yield (KO NUE)
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2100962A1 (de) 2008-03-12 2009-09-16 Biogemma Pflanzen mit verbesserter Widerstandsfähigkeit gegen Pathogene
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2331071A1 (de) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Neue multimodulare anordnung zur intrazellulären abgabe
EP2184351A1 (de) 2008-10-30 2010-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polynukleotid-kondierende Caryophyllen-Synthase und ihre Verwendung
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US10519458B2 (en) 2009-04-22 2019-12-31 Basf Plant Science Company Gmbh Whole seed specific promoter
WO2011030312A1 (en) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
SI2488203T1 (sl) 2009-10-16 2017-07-31 Omeros Corporation Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa
DK2493871T3 (da) 2009-10-30 2014-11-10 Prestwick Chemical Sas Nye oximderivater samt deres anvendelse som allosteriske modulatorer af metabotropiske glutamatreceptorer
EP2322149A1 (de) 2009-11-03 2011-05-18 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Ischämie
PL2510001T3 (pl) 2009-12-08 2016-06-30 Abbvie Deutschland Monoklonalne przeciwciało przeciwko białku RGM A do zastosowania w leczeniu zwyrodnienia warstwy włókien nerwowych siatkówki (RNFL)
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
US8476485B2 (en) 2010-06-24 2013-07-02 Academia Sinica Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CA2817071C (en) 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ709997A (en) 2011-04-08 2016-03-31 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
EP2734621B1 (de) 2011-07-22 2019-09-04 President and Fellows of Harvard College Beurteilung und verbesserung einer nukleasespaltungsspezifität
US20150017091A1 (en) 2011-08-18 2015-01-15 Cornell University Detection and treatment of metastatic disease
WO2013039880A1 (en) 2011-09-12 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers and therapeutic targets of hepatocellular cancer
CA2859564C (en) 2011-12-16 2020-04-14 Board Of Trustees Of Michigan State University P-coumaroyl-coa:monolignol transferase
IL316441A (en) 2012-01-27 2024-12-01 Abbvie Inc Composition and method for diagnosing and treating diseases associated with axonal degeneration of nerve cells
EP2825209B1 (de) 2012-03-14 2018-08-29 University of Central Florida Research Foundation, Inc. Neurofibromatose-therapeutika und screening dafür
EP2666775A1 (de) 2012-05-21 2013-11-27 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
WO2014127835A1 (en) 2013-02-22 2014-08-28 Christian-Albrechts-Universität Zu Kiel Plant-derived resistance gene
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
CA2926385A1 (en) 2013-10-17 2015-04-23 Omeros Corporation Methods for treating thrombotic microangiopathies associated with masp-2dependent complement activation
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
KR102535223B1 (ko) 2013-12-18 2023-05-30 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 장쇄 다중불포화 지방산을 포함하는 지질
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
EP3000814A1 (de) 2014-09-26 2016-03-30 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
EP3365357B1 (de) 2015-10-23 2024-02-14 President and Fellows of Harvard College Entwickelte cas9-proteine für geneditierung
WO2017083371A1 (en) 2015-11-09 2017-05-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
KR102475622B1 (ko) 2016-01-05 2022-12-08 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
GEP20237466B (en) 2016-03-31 2023-01-25 Univ Leicester Methods of inhibiting angiogenesis in patient
MA44031B1 (fr) 2016-05-26 2021-06-30 Nunhemes B V Plantes produisant des fruits sans graines
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nuclear base editors and their uses
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
ES2949801T3 (es) 2017-01-09 2023-10-03 Whitehead Inst Biomedical Res Métodos para alterar la expresión génica mediante la perturbación de multímeros de factores de transcripción que estructuran bucles reguladores
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US10883089B2 (en) 2017-04-04 2021-01-05 Wisconsin Alumni Research Foundation Feruloyl-CoA:monolignol transferases
US10883090B2 (en) 2017-04-18 2021-01-05 Wisconsin Alumni Research Foundation P-coumaroyl-CoA:monolignol transferases
WO2019018451A2 (en) 2017-07-17 2019-01-24 The Regents Of The University Of Colorado COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
EP3676376B1 (de) 2017-08-30 2025-01-15 President and Fellows of Harvard College Hocheffiziente baseneditoren mit gam
EP3697906A1 (de) 2017-10-16 2020-08-26 The Broad Institute, Inc. Verwendungen von adenosinbasiseditoren
EP3797160A1 (de) 2018-05-23 2021-03-31 The Broad Institute Inc. Baseneditoren und verwendungen davon
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
MA52797A (fr) 2018-05-29 2021-04-14 Omeros Corp Inhibiteurs de masp -2 et procédés d'utilisation
EP3806619A1 (de) 2018-06-15 2021-04-21 Nunhems B.V. Kernlose wassermelonenpflanzen mit modifikationen in einem abc-transporter-gen
WO2020097518A1 (en) 2018-11-09 2020-05-14 Wisconsin Alumni Research Foundation Bahd acyltransferases
EP3942042A1 (de) 2019-03-19 2022-01-26 The Broad Institute, Inc. Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
MX2022006750A (es) 2019-12-04 2022-06-14 Omeros Corp Inhibidores de masp-2 y metodos de uso.
CA3159176A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
EP4069676A1 (de) 2019-12-04 2022-10-12 Omeros Corporation Masp-2-hemmer und verfahren zur verwendung
CN116096873A (zh) 2020-05-08 2023-05-09 布罗德研究所股份有限公司 同时编辑靶标双链核苷酸序列的两条链的方法和组合物
US20240011030A1 (en) 2020-08-10 2024-01-11 Novartis Ag Treatments for retinal degenerative diseases
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance
WO2024042160A1 (en) 2022-08-26 2024-02-29 Mitodicure Gmbh Use of a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
DE3642623A1 (de) * 1986-12-13 1988-06-23 Burbach & Bender Ohg Gasspuelstein fuer metallurgische gefaesse
DE3939771A1 (de) * 1989-12-01 1991-06-06 Behringwerke Ag Verfahren zur biologischen inaktivierung von nukleinsaeuren

Also Published As

Publication number Publication date
CN1102174C (zh) 2003-02-26
JP3046318B2 (ja) 2000-05-29
DK175956B1 (da) 2005-08-22
AU2800789A (en) 1989-07-19
NO902661L (no) 1990-08-14
KR900700603A (ko) 1990-08-16
NO308610B1 (no) 2000-10-02
ES2065919T3 (es) 1995-03-01
DK143390A (da) 1990-08-14
DE3852539T2 (de) 1995-05-04
EP0321201A3 (en) 1990-01-10
GR3015374T3 (en) 1995-06-30
EP0640688A1 (de) 1995-03-01
NZ227332A (en) 1991-08-27
AU632993B2 (en) 1993-01-21
CA1340831C (en) 1999-11-30
NO312105B1 (no) 2002-03-18
EP0321201B2 (de) 2004-11-24
MC2115A1 (fr) 1991-07-05
NO20000369D0 (no) 2000-01-25
EP0321201A2 (de) 1989-06-21
EP0321201B1 (de) 1994-12-21
DE3852539T3 (de) 2005-08-04
KR970010758B1 (ko) 1997-06-30
WO1989005852A1 (en) 1989-06-29
HU211891A9 (en) 1995-12-28
DE3852539D1 (de) 1995-02-02
JPH03502638A (ja) 1991-06-20
DK143390D0 (da) 1990-06-12
CN1033838A (zh) 1989-07-12
RO114469B1 (ro) 1999-04-30
NO20000369L (no) 1990-08-14
NO902661D0 (no) 1990-06-14
FI104562B (fi) 2000-02-29
FI902923A0 (fi) 1990-06-12
HUT54407A (en) 1991-02-28
AR243935A1 (es) 1993-09-30
ES2065919T5 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
ATE115999T1 (de) Ribozyme.
ES2019689B3 (es) Caudalimetro.
FI831659L (fi) Tvaodelad ask.
DE3888991D1 (de) Aminokohlenwasserstoff-substituierte Ketoximosilane.
FI871559A0 (fi) Isbrytare.
FI885113A (fi) Tixotrop vattenhaltig flytande tvaettmedelskomposition foer automatisk diskning.
IT8421396A0 (it) Vaglio.
FI870712A0 (fi) Mineralullcentrifug.
FI883691A0 (fi) Spel.
FI882776A (fi) Nytt foerfarande.
NO880953D0 (no) 4-benzyl-piperazinyl-hydrazoner.
FI871591A0 (fi) Saxkran.
ES2019679B3 (es) Mejoras en burletes.
NO870246D0 (no) Loepbrekker.
FI884302A (fi) Traedprocessoraggregat.
FI872130A0 (fi) Foerbaettringar avseende skyddsplaot foer byggnader.
FI872670A0 (fi) Spel.
NO875149D0 (no) Maaletrommel-system.
ES269598Y (es) Juguete.
IT8321724V0 (it) Struttura di giocattolo passatempo.
ES521579A0 (es) Mejoras introducidas en arados.
FI81425C (fi) Taksnoehyvel.
FI833621A (fi) Tvaodelad ask.
FI871973A0 (fi) Lie.
FI871349A (fi) Stoedfot foer staengselpelare.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0321201

Country of ref document: EP

EELA Cancelled due to lapse of time